Acuitas Investments LLC bought a new position in KORU Medical Systems, Inc. (NASDAQ:KRMD – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 402,494 shares of the company’s stock, valued at approximately $1,441,000. Acuitas Investments LLC owned approximately 0.87% of KORU Medical Systems as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in shares of KORU Medical Systems by 189.5% in the first quarter. Goldman Sachs Group Inc. now owns 242,781 shares of the company’s stock worth $617,000 after buying an additional 158,914 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of KORU Medical Systems in the first quarter worth approximately $63,000. Jane Street Group LLC lifted its stake in shares of KORU Medical Systems by 136.7% in the first quarter. Jane Street Group LLC now owns 163,137 shares of the company’s stock worth $414,000 after buying an additional 94,214 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of KORU Medical Systems by 927.4% in the first quarter. Cubist Systematic Strategies LLC now owns 77,280 shares of the company’s stock worth $196,000 after buying an additional 69,758 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new position in KORU Medical Systems during the first quarter valued at approximately $239,000. Institutional investors own 58.60% of the company’s stock.
KORU Medical Systems Price Performance
KRMD opened at $4.25 on Friday. The company has a current ratio of 2.91, a quick ratio of 2.25 and a debt-to-equity ratio of 0.01. KORU Medical Systems, Inc. has a 1-year low of $1.86 and a 1-year high of $5.05. The company has a market capitalization of $196.52 million, a PE ratio of -47.22 and a beta of 0.49. The firm’s 50 day simple moving average is $4.08 and its two-hundred day simple moving average is $3.44.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.63.
Get Our Latest Stock Report on KORU Medical Systems
KORU Medical Systems Profile
KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria.
Featured Articles
- Five stocks we like better than KORU Medical Systems
- Trading Stocks: RSI and Why it’s Useful
- UnitedHealth’s Moment of Truth: 3 Bullish Signals to Watch For
- The How And Why of Investing in Oil Stocks
- Warner Bros. Bidding War Potential: How High Could WBD Shares Go?
- What is a SEC Filing?
- Analysts Eye 30% Upside in Netflix After Q3 Earnings Crash
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
